Is there a link between menopause insomnia and weight loss on a GLP-1?

Key takeaways

Dr. Linda's take

The women who ask me this question are usually not asking out of curiosity. They are asking because they have been awake since 3 a.m. for the better part of a year, the scale has stopped moving, and somewhere in the back of their mind is a suspicion that the two facts are connected. They are right that the two are connected. What they usually want to know next is whether a medication is part of that connection, in either direction. Could it fix the sleep? Could it be wrecking the sleep?

I want to answer this precisely rather than reassuringly, because the precise answer is genuinely useful. There is real science on sleep and body weight in midlife. There is real, FDA-reviewed trial evidence on one of these medicines and one specific sleep disorder. And there is a gap where a direct answer about menopause insomnia should be. Knowing which of those three you are standing in changes what you do next, so let me walk you through all three.

Why does sleep fall apart around menopause?

Because several things go wrong at once, and they compound each other.

The first is hormonal and symptomatic. Vasomotor symptoms are the most common menopausal symptoms reported by 75% to 85% of postmenopausal women. Hot flashes and night sweats do not politely wait for daytime, and waking up drenched at 2 a.m. is a sleep problem dressed as a temperature problem.

The second is that the baseline rate of sleep trouble simply climbs. The prevalence of sleep disorders is variable, ranging from 16% to 42% in premenopausal women, from 39% to 47% in perimenopausal women, and from 35% to 60% in postmenopausal women. That is a real, measured shift, not a story you are telling yourself.

The third is breathing, and it is the most under-recognised of the three. We come back to it below. For the behavioural side, we have covered it already in why your body fights you on sleep and weight in perimenopause and in tiny habit shifts for perimenopause insomnia. This article is about the medication question specifically.

Does bad sleep actually make weight loss harder, or does it just feel that way?

It is not just a feeling, and this is the part of the answer that is best supported.

Start with appetite. In a large population study, participants with short sleep had reduced leptin and elevated ghrelin. Those are the two hormones that argue with each other about whether you are hungry. These differences in leptin and ghrelin are likely to increase appetite, possibly explaining the increased BMI observed with short sleep duration. So a bad night does not just make you tired. It arrives the next day as a louder appetite signal that you then have to negotiate with.

Then there is what happens when you are actively trying to lose weight while underslept. In a controlled crossover study of adults on a reduced-calorie diet, sleep curtailment decreased the fraction of weight lost as fat by 55% (1.4 vs. 0.6 kg with 8.5 vs. 5.5-h sleep opportunity, P=0.043) and increased the loss of fat-free body mass by 60% (1.5 vs. 2.4 kg, P=0.002). Read that carefully, because it is not a statement about the scale. Total weight loss was similar. What changed was its composition: less of the loss came from fat and more came from lean tissue.

The authors put it plainly. Lack of sufficient sleep may compromise the efficacy of typical dietary interventions for weight loss and related metabolic risk reduction. That is a small study, and I hold it loosely, but it lines up with what women describe: the effort is the same, the result is worse. We have written more about that pattern in how sleep influences weight loss success.

Where is the sleep apnea piece, and why does it matter after menopause?

This is the part most women have never been told, and it is where the medication evidence is actually strong.

Menopause changes your airway risk. In the Wisconsin Sleep Cohort Study, odds ratios, adjusted for age, body habitus, smoking, and other potential confounding factors, for 5 or more apnea and hypopnea events per hour were 1.2 (0.7, 2.2) with perimenopause and 2.6 (1.4, 4.8) with postmenopause; odds ratios for 15 or more apnea and hypopnea events per hour were 1.1 (0.5, 2.2) with perimenopause and 3.5 (1.4, 8.8) with postmenopause. The investigators concluded that the menopausal transition is significantly associated with an increased likelihood of having sleep-disordered breathing, independent of known confounding factors. A separate review notes that the incidence of OSA is significantly increased in postmenopausal women.

This matters enormously for the question you came here with. Obstructive sleep apnea in women is routinely mistaken for insomnia, because what you notice is not snoring, it is waking up repeatedly and feeling wrecked. The recommendation from that same cohort study is direct: evaluation for sleep-disordered breathing should be a priority for menopausal women with complaints of snoring, daytime sleepiness, or unsatisfactory sleep. If you are a postmenopausal woman who has been treating herself for insomnia for three years, that sentence deserves a conversation with a clinician.

Is there any medication evidence linking a GLP-1 to sleep?

Yes, and it is specifically about apnea.

Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. That indication rests on the SURMOUNT-OSA trials. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour with tirzepatide and -5.3 events per hour with placebo, for an estimated treatment difference of -20.0 events per hour. The overall finding was that among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes.

Those patient-reported outcomes are worth pausing on, because they are the closest thing we have to a measure of how people said they actually slept. At Week 52, compared with placebo, tirzepatide-treated participants reported significantly improved Patient-Reported Outcomes Measurement Information System (PROMIS) Short-Form Sleep-related Impairment 8a scores, PROMIS Short-Form v1.0 Sleep Disturbance 8b scores, Functional Outcomes of Sleep Questionnaire Activity-Level scores, EQ-5D-5L scores, and most domains of the Short-Form 36 Health Survey, Version 2.

So people slept better and felt better. But note what the study population was. Everyone had diagnosed moderate-to-severe apnea and obesity. This is a treatment for a breathing disorder, and the sleep improvement follows from treating that disorder.

So is there a proven link between menopause insomnia and weight loss on a GLP-1?

Here is where I have to be honest with you rather than tidy.

No. That specific link has not been established. The SURMOUNT-OSA population was not a menopause population and was not even mostly female: the enrolled participants comprised 30.3% females with a mean age of 49.7 years. In fact, because OSA is more common in males, the trial capped male enrollment at approximately 70% to ensure sufficient female participation. Nothing in that trial was analysed by menopausal status. And insomnia, the lying-awake-at-3-a.m. kind, was not what was being treated.

What we can say is a chain of separately supported links rather than one proven arrow. Menopause raises the odds of disturbed sleep and of sleep-disordered breathing. Disturbed sleep is associated with hungrier appetite hormones and a worse body-composition result when you cut calories. And one of these medicines has trial evidence and an approval for one particular sleep disorder that becomes more common after menopause. Each of those is real. Stringing them into a promise that one of these medicines will fix your menopause insomnia is not something the evidence supports, and I am not going to tell you it does.

On the other direction, the worry that these medicines are causing your insomnia: the most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. Sleeplessness is not the signal that dominates the trial safety data. That does not mean your experience is not real, and anything new that starts after a medication does belongs in front of your prescriber rather than in a forum thread.

If you want a sense of where you sit generally, our eligibility quiz is a starting point, and the broader midlife picture is covered in why perimenopause weight gain happens even when your diet has not changed and what women in their 40s and 50s need to know about insomnia and weight loss.

The bottom line

The searcher's instinct is sound and the science is partly on her side. Sleep and weight regulation in midlife are genuinely intertwined, and the menopause transition makes sleep harder in ways that are measurable rather than imagined. Where the evidence stops is at the specific claim that one of these medicines treats menopause insomnia, because that trial has not been run. What has been run, and run well, is a trial showing that tirzepatide improves obstructive sleep apnea in adults with obesity, and apnea is a condition that becomes more likely after menopause and is regularly mistaken for insomnia in women. That is not the answer to the question you asked, but it may be the more useful one. If your nights are broken, the first move is not choosing a medication. It is finding out what is actually breaking them, with a clinician who will take the question seriously.

References

1. Lee J, Han Y, Cho HH, Kim MR (2019). Sleep Disorders and Menopause. Journal of Menopausal Medicine (PMC6718648). https://pmc.ncbi.nlm.nih.gov/articles/PMC6718648/ (Accessed 2026-07-20).
2. Taheri S, Lin L, Austin D, Young T, Mignot E (2004). Short Sleep Duration Is Associated with Reduced Leptin, Elevated Ghrelin, and Increased Body Mass Index. PLoS Medicine (PMC535701). https://pmc.ncbi.nlm.nih.gov/articles/PMC535701/ (Accessed 2026-07-20).
3. Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Penev PD (2010). Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine (PMC2951287). https://pmc.ncbi.nlm.nih.gov/articles/PMC2951287/ (Accessed 2026-07-20).
4. Young T, Finn L, Austin D, Peterson A (2003). Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. American Journal of Respiratory and Critical Care Medicine. PubMed PMID 12615621. https://pubmed.ncbi.nlm.nih.gov/12615621/ (Accessed 2026-07-20).
5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine. PubMed PMID 38912654. https://pubmed.ncbi.nlm.nih.gov/38912654/ (Accessed 2026-07-20).
6. Malhotra A, Bednarik J, Chakladar S, et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemporary Clinical Trials (PMC11168245). https://pmc.ncbi.nlm.nih.gov/articles/PMC11168245/ (Accessed 2026-07-20).
7. Kanu C, Shinde S, Weaver TE, Poon JL, Malhotra A (2025). Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Medicine (PMC12720398). https://pmc.ncbi.nlm.nih.gov/articles/PMC12720398/ (Accessed 2026-07-20).
8. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, solution - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-20).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-21.*